PBS News

Updated Price Disclosure Guidelines, Price Disclosure webpages and Price Disclosure Dispute Resolution Process

Page last updated: 8 June 2022

Amendments made to the National Health Act 1953 and National Health (Pharmaceutical Benefits) Regulations 2017 by the National Health Amendment (Enhancing the Pharmaceutical Benefits Scheme) Act 2021 (Cth) (Amendment Act) and the National Health (Pharmaceutical Benefits) Amendment (2021 Measures No. 1) Regulations 2021 (Cth) (Amendment Regulations) give effect to the comitments in the new Strategic Agreements with the medicines industry (2022-2027). Legislative amendments take effect from 1 July 2022 and include the following changes to price disclosure:

  • Introduction of floor prices for designated brands
  • Changes to the threshold for applying price disclosure price reductions
  • Changes to the timing for removal of originator brands from calculations 
  • Changes to exclusion of supplies to public hospitals within disclosed data
  • Changes to adjusted net revenue calculations

To reflect these reforms, the Pharmaceutical Benefits Scheme Price Disclosure Guidelines, Price Disclosure webpages and the Price Disclosure dispute resolution process have been updated. A Fact Sheet regarding Price Disclosure Reforms under the New Strategic Agreement Fact Sheet (PDF 735 KB) - (Word 443 KB) is also available.

The Price Disclosure Guidelines are intended to provide guidance to responsible persons regarding their Price Disclosure obligations, how to comply, and the consequences of non-compliance. The Guidelines also provide details of the Price Disclosure process, such as how data is collected and processed, how the outcomes of calculations are applied to the prices of relevant pharmaceutical items and what options are available to Responsible Persons to raise disputes. In addition to the reforms, the Price Disclosure Guidelines have also been updated to reflect the process for notifying the Department when there is a change of responsible person for a brand during a price disclosure data collection period (see Part 5.4 of the Price Disclosure Guidelines).